Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
United European Gastroenterol J ; 9(10): 1119-1127, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34873866

RESUMO

BACKGROUND: Hepatitis D virus (HDV) coinfection aggravates the course of hepatitis B virus (HBV). The prevalence of HDV in Austria is unknown. OBJECTIVE: This national study aimed at (i) recording the prevalence of HDV-infection in Austria and (ii) characterizing the "active" HDV cohort in Austria. METHODS: A total of 10 hepatitis treatment centers in Austria participated in this multicenter study and retrospectively collected their HDV patients between Q1/2010 and Q4/2020. Positive anti-HDV and/or HDV-RNA-polymerase chain reaction (PCR) results were retrieved from local database queries. Disease severity was assessed by individual chart review. Viremic HDV patients with clinical visits in/after Q1/2019 were considered as the "active" HDV cohort. RESULTS: A total of 347 anti-HDV positive patients were identified. In 202 (58.2%) patients, HDV-RNA-PCR test was performed, and 126/202 (62.4%) had confirmed viremia. Hepatocellular carcinoma was diagnosed in 7 (5.6%) patients, 7 (5.6%) patients underwent liver transplantation, and 11 (8.7%) patients died during follow-up. The "active" Austrian HDV cohort included 74 (58.7%) patients: Evidence for advanced chronic liver disease (ACLD, i.e., histological F3/F4 fibrosis, liver stiffness ≥10 kPa, varices, or hepatic venous pressure gradient ≥6 mmHg) was detected in 38 (51.4%) patients, including 2 (5.3%) with decompensation (ascites/hepatic encephalopathy). About 37 (50.0%) patients of the "active" HDV cohort had previously received interferon treatment. Treatment with the sodium-taurocholate cotransporting polypeptide inhibitor bulevirtide was initiated in 20 (27.0%) patients. CONCLUSION: The number of confirmed HDV viremic cases in Austria is low (<1% of HBV patients) but potentially underestimated. Testing all HBV patients will increase the diagnostic yield. More than half of viremic HDV patients had ACLD. Improved HDV testing and workup strategies will facilitate access to novel antiviral therapies.


Assuntos
Hepatite D/epidemiologia , Adulto , Áustria/epidemiologia , Carcinoma Hepatocelular/epidemiologia , Progressão da Doença , Feminino , Hepatite D/diagnóstico , Humanos , Cirrose Hepática/epidemiologia , Cirrose Hepática/virologia , Neoplasias Hepáticas/epidemiologia , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos
2.
Zoonoses Public Health ; 66(7): 842-851, 2019 11.
Artigo em Inglês | MEDLINE | ID: mdl-31419070

RESUMO

We investigated the prevalence of Hepatitis E Virus (HEV), Leptospira and Ascaris suum (A. suum) seropositivity, and of nasal methicillin-resistant Staphylococcus aureus (MRSA) colonization among Austrian practising veterinarians, and assessed the association with occupational swine livestock exposure. The 261 participants completed a questionnaire on demographics, intensity of occupational swine livestock contact and glove use during handling animals and their secretions. Participants' blood samples were tested for HEV, Leptospira and A. suum seropositivity and nasal swabs cultured for MRSA. We compared swine veterinarians (defined as >3 swine livestock visits/week) to non-swine veterinarians (≤3 swine livestock visits/week) with regard to the outcomes through calculating prevalence ratio (PR) and 95% confidence interval (CI). Furthermore, the relationship between occupational swine livestock contact and the study outcomes was examined by age (3 occupational swine livestock visits per week is associated with HEV and A. suum seropositivity and nasal MRSA colonization and that glove use may play a putative preventive role in acquiring HEV and A. suum. Further analytical epidemiological studies have to prove the causality of these associations.


Assuntos
Ascaris suum , Vírus da Hepatite E , Leptospira , Staphylococcus aureus Resistente à Meticilina , Suínos , Médicos Veterinários , Adulto , Animais , Anticorpos Antibacterianos , Anticorpos Anti-Helmínticos , Anticorpos Antivirais , Ascaríase/epidemiologia , Áustria/epidemiologia , Portador Sadio , Estudos Transversais , Feminino , Hepatite E/epidemiologia , Humanos , Leptospirose/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Soroepidemiológicos , Testes Sorológicos , Infecções Estafilocócicas/epidemiologia , Infecções Estafilocócicas/microbiologia , Zoonoses
3.
Wien Klin Wochenschr ; 128 Suppl 4: 337-76, 2016 Aug.
Artigo em Alemão | MEDLINE | ID: mdl-27457874

RESUMO

Immunosuppression of various origins is associated with an increased risk of infection; therefore the prevention of infectious diseases by vaccination is especially important in immunocompromised patients. However, the response to vaccinations is often reduced in these risk groups and the application of live vaccines is contraindicated during immunosuppression.In the following expert statement, recommendations for vaccination were created on the basis of current evidence and theoretical/immunological considerations. A first, general part elaborates on efficacy and safety of vaccinations during immunosuppression, modes of action of immunosuppressive medications and recommended time intervals between immunosuppressive treatments and vaccinations. A core piece of this part is a graduation of immunosuppression into three stages, i. e. no relevant immunosuppression, mild to moderate and severe immunosuppression and the assignment of various medications (including biologicals) to one of those stages; this is followed by an overview of possible and necessary vaccinations in each of those stages.The second part gives detailed vaccination guidelines for common diseases and therapies associated with immunosuppression. Primary immune deficiencies, chronic kidney disease, diabetes mellitus, solid and hematological tumors, hematopoetic stem cell transplantation, transplantation of solid organs, aspenia, rheumatological-, gastroenterologic-, dermatologic-, neurologic diseases, biologicals during pregnancy and HIV infection are dealt with.These vaccination guidelines, compiled for the first time in Austria, aim to be of practical help for physicians to facilitate and improve vaccination coverage in immunocompromised patients and their household members and contact persons.


Assuntos
Hospedeiro Imunocomprometido , Vacinação , Vacinas/administração & dosagem , Alergia e Imunologia/normas , Áustria , Contraindicações , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/normas , Vacinas/normas
4.
J Infect Dis ; 202(12): 1770-9, 2010 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-21067369

RESUMO

INTRODUCTION: Acute hepatitis C virus (HCV) infection is rarely studied, but virus sequence evolution and host-virus dynamics during this early stage may influence the outcome of infection. Hypervariable region 1 (HVR1) is genetically diverse and under selective pressure from the host immune response. We analyzed HVR1 evolution by frequent sampling of an acutely infected HCV cohort. METHODS: Three or more pretreatment samples were obtained from each of 10 acutely infected subjects. Polymerase chain reaction amplification was performed with multiple primer combinations to identify the full range of sequences present. Positive samples were cloned and sequenced. Phylogenetic analyses were used to assess viral diversity. RESULTS: Eight of the 10 subjects were coinfected with at least 2 HCV subtypes. Multiple subtypes were detected in individual samples, and their relative proportions changed through acute infection. The subjects with the most complex subtype structure also had a dynamic viral load; however, changes in viral load were not directly linked to changes in subtype. CONCLUSIONS: This well-sampled cohort with acute HCV infection was characterized by dynamic coinfection with multiple viral subtypes, representing a highly complex virologic landscape extremely early in infection.


Assuntos
Hepacivirus/imunologia , Hepacivirus/patogenicidade , Hepatite C/virologia , Interações Hospedeiro-Patógeno , Polimorfismo Genético , RNA Viral/genética , Adolescente , Adulto , Áustria , Clonagem Molecular , Feminino , Genótipo , Hepacivirus/genética , Hepacivirus/isolamento & purificação , Hepatite C/diagnóstico , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Análise de Sequência de DNA , Proteínas do Envelope Viral/genética
5.
Wien Klin Wochenschr ; 122(9-10): 280-302, 2010 May.
Artigo em Alemão | MEDLINE | ID: mdl-20443069

RESUMO

Hepatitis B is the most common chronic viral infection of the liver. Chronic hepatitis B is estimated to affect at least 350 million people worldwide and is the leading cause of death from liver disease. There have been dramatic developments both in the diagnostic field and in drug treatment of chronic hepatitis B. Today, chronic hepatitis B is a well manageable disease in the vast majority of cases and the main challenge remains the detection of affected patients at an early enough disease stage to prevent end-stage liver disease and its complications. The rapid pace of drug development mandated an update of the Austrian guidelines on the treatment of hepatitis B, which after 1994 and 1998 were now dating back to 2005 in their third version. All chapters from the 3. consensus statement from 2005 were renewed except for the chapter on liver biopsy, which is still valid in its 2005-version. In particular, virologic parameters take now center stage for treatment decisions, HBV-genotyping is now being considered for the choice of treatment, and the oral first line treatment for chronic hepatitis B has been changed. Overall this consensus statement accounts for the major advances in the management of hepatitis B and significantly changes clinical management of patients with hepatitis B in Austria.


Assuntos
Hepatite B/diagnóstico , Hepatite B/terapia , Guias de Prática Clínica como Assunto , Padrões de Prática Médica/normas , Áustria , Humanos
6.
J Neurovirol ; 12(4): 322-7, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16966222

RESUMO

In Central European tick-borne encephalitis (TBE) mechanisms of tissue destruction are poorly understood. To evaluate the contribution of immunological mechanisms to tissue injury, the authors immunohistochemically analyzed paraffin-embedded autoptic brain tissue of 26 human TBE cases. In the parenchymal compartment, there was a predominance of macrophages/microglia and cytotoxic T cells. In addition, it was found that granzyme B-expressing lymphocytes were in close contact with TBE-expressing neurons up-regulating caspase-3. These findings indicate that cellular and humoral pathways of the immune system, especially granzyme B-releasing cytotoxic T cells and macrophages/microglia, mainly contribute to tissue destruction in TBE.


Assuntos
Encéfalo/imunologia , Encefalite Transmitida por Carrapatos/imunologia , Adolescente , Adulto , Idoso , Animais , Apoptose/fisiologia , Encéfalo/patologia , Encéfalo/virologia , Encefalite Transmitida por Carrapatos/patologia , Encefalite Transmitida por Carrapatos/virologia , Flavivirus , Granzimas/biossíntese , Granzimas/imunologia , Humanos , Imuno-Histoquímica , Inflamação/imunologia , Ixodes/virologia , Macrófagos/imunologia , Microglia/imunologia , Pessoa de Meia-Idade , Linfócitos T Citotóxicos/enzimologia , Linfócitos T Citotóxicos/imunologia
7.
J Infect Dis ; 187(3): 345-51, 2003 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-12552417

RESUMO

Virological and clinical data from 73 hepatitis C virus (HCV)-infected pregnant women who gave birth to 75 children were merged retrospectively, by logistic regression analysis, to investigate risk factors for vertical transmission of HCV. Eighty-two percent of the HCV-infected mothers were HCV-RNA-positive during pregnancy, and 10% were coinfected with human immunodeficiency virus (HIV). Nine children were HCV infected, 1 was HIV infected, but none was HIV-HCV coinfected. Among vaginal deliveries, the mean HCV load of mothers who transmitted HCV to their infants was higher than that of those who did not (8.1 x 10(5) vs. 1.4 x 10(4) copies/mL; P=.056). A reduction in umbilical cord-blood pH (relative risk, 3.9; P=.04) or the occurrence of perineal or vaginal laceration (relative risk, 6.4; P=.028) during vaginal delivery significantly increased the risk of vertical HCV transmission. In conclusion, high maternal viremia, infantile hypoxia, and intrapartum exposure to virus-contaminated maternal blood increased the risk of HCV transmission during vaginal deliveries. Consequently, cesarean section may reduce the risk of vertical HCV transmission in selected cases.


Assuntos
Hepatite C/sangue , Hepatite C/transmissão , Transmissão Vertical de Doenças Infecciosas , Feminino , Sangue Fetal/virologia , Seguimentos , HIV/genética , HIV/isolamento & purificação , Infecções por HIV/sangue , Infecções por HIV/complicações , Infecções por HIV/prevenção & controle , Infecções por HIV/transmissão , Hepacivirus/genética , Hepacivirus/isolamento & purificação , Hepatite C/complicações , Hepatite C/prevenção & controle , Humanos , Concentração de Íons de Hidrogênio , Recém-Nascido , Modelos Logísticos , Parto/sangue , Gravidez , Complicações Infecciosas na Gravidez/sangue , Complicações Infecciosas na Gravidez/virologia , RNA Viral/sangue , Estudos Retrospectivos , Fatores de Risco , Carga Viral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA